目的观察英夫利昔对实验性免疫性肌炎(EIM)的治疗效果。
Objective To assess the clinical effects of infliximab in experimental immune myositis (EIM).
结论英夫利昔对克罗恩病瘘管具有良好的近期闭合作用，使用安全。
Conclusions: Infliximab is effective for fistula of Crohn s disease and is safe during short term therapy.
另外，使用英夫利昔单抗不会增加减少类固醇用量而不复发的患者比率。
Moreover, infliximab use did not increase the proportion of patients who were able to taper their steroid dosages without relapse.
研究者总结到，英夫利昔持续治疗银屑病产生的治疗效果要好于按需治疗。
Overall, the researchers conclude that maintenance infliximab therapy provided a better patient response than did as-needed therapy.
目的检测英夫利昔治疗是否可影响生存素水平及生存素是否可预测对英夫利昔的临床疗效。
Objectives: The object of this study was to examine if infliximab treatment affects levels of survivin and if survivin may be used as a predictor of clinical response to infliximab.
疾病活动度，ANCA,IL23R基因型状态决定了溃疡性结肠炎病人对英夫利昔单抗的早期应答。
Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis.
结果：通过硬化治疗技术，在肠管狭窄区的远端和中间部分注射英夫利昔单抗，全部3名患者的结肠狭窄都得到了扩张。
Results: in all 3 patients, dilation of a colonic stricture was accomplished by injection of infliximab, via the sclerotherapy technique, into the distal and medial portions of the stricture.
母亲孕期接受英夫利昔单抗治疗的婴儿，在接受活疫苗免疫时应延期，直到至少6个月血清中均检测不到英夫利昔单抗。
Vaccination with live viruses should be postponed in infants exposed to infliximab in utero, until serum levels are undetectable which may require more than 6 months.
这些病人中，通过联合治疗的有69%的人获得缓解而在英夫利昔单抗组中为57%，硫唑嘌呤组中只有28%的到缓解。
Among these patients, 69% achieved remission with the combination treatment compared to 57% of those on Remicade alone and to 28% of those on azathioprine alone.
经过26周的治疗，联合用药的病人中有57%获得缓解，与之相比，在单用英夫利昔单抗组中只有44%而单用硫唑嘌呤组中只有30%得到缓解。
After 26 weeks of treatment, patients getting the combination had a 57% chance of disease remission, compared to 44% of those getting Remicade alone and to 30% of those getting azathioprine alone.
经过26周的治疗，联合用药的病人中有57%获得缓解，与之相比，在单用英夫利昔单抗组中只有44%而单用硫唑嘌呤组中只有30%得到缓解。
After 26 weeks of treatment, patients getting the combination had a 57% chance of disease remission, compared to 44% of those getting Remicade alone and to 30% of those getting azathioprine alone.
应用推荐